Researchers analyzed data from the CANVAS Program and found that canagliflozin treatment led to a 17% reduction in urinary albumin to creatinine ratio from baseline estimated glomerular filtration rate among patients with type 2 diabetes and with or at high risk for cardiovascular disease and with preserved renal function, as well as a 23% reduction among those with reduced eGFR. Treatment with canagliflozin also resulted in a relative risk reduction in the composite endpoint of eGFR decline, end-stage kidney disease or renal death.
Diabetes patients may see improved renal outcomes with canagliflozin
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.